Colin Begg

Maximilian Siebert and colleagues investigated the strength of evidence supporting EMA drug approvals, finding 78% supported by RCTs but over 50% supported only by surrogate endpoints. @Stanford @FDAdrugs @FDA @HarvardMIT_CRS

Stef Baas and colleagues argue that ethics must take a central stage when deciding whether to select a fixed or an adaptive design for a randomized clinical trial. Commentaries provided by Janet Wittes and Stephen Senn. @MRC_BSU @CancerEthicsDoc

Additional crossovers in cluster randomized crossover trials DO NOT always increase statistical power! This paper by KM Tanvir and colleagues describes when additional crossovers don't provide any additional benefit. @MonashUni @UnivofDhaka

Spencer Cho and colleagues examine the evolving role of the placebo in non-inferiority trials as an alternative to an existing, unproven treatment. They highlight common methodological gaps and call for greater transparency in future trials. @UOttawa #clinicaltrials

Is multiple imputation more powerful than complete case analysis in clinical trials? A systematic review by Thomas Sullivan found multiple imputation often led to noticeable changes in the effect estimate but did not demonstrate consistent precision advantages. #ClinicalTrials